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Purpose: The surgical treatment of fistulae that originate from aortic aneurysms or 
prosthetic aortic grafts carries a high mortality rate. We investigated whether in situ 
repair with cryopreserved aortic homografts would improve the outcome. 
Methods: Between April 1994 and June 1996, 11 patients (mean age, 62 -+ 10 years) with 
aortobronchial, aortoesophageal, or aortointestinal fistulae originating from mycotic 
aneurysms (five of 12) or prosthetic aortic grafts (six of 12) underwent in situ replace- 
ment of the thoracic (seven of 10) or abdominal (four of 10) aorta with homografts. 
Emergency surgery was performed in eight of 11 patients (73%). 
Results: The hospital mortality rate was 9%; there was one sudden cardiac death on the 
seventh postoperative day. The mean hospital stay was 42 -+ 26 days (range, 21 to 90 
days). After surgery, antibiotics were given for 38 + 6 days (range, 28 to 42 days). 
Neither reinfection, suture line rupture, nor anastomotic aneurysms were observed by 
magnetic resonance angiography, computed tomography, angiography, or transesopha- 
geal echocardiography after 14.3 + 8.2 months (range, 6 to 31 months). In one patient, 
percutaneous vascular stent placement was necessary after 18 months for an anastomotic 
stenosis of a thoracic homograft. 
Conclusions: In situ repair with cryopreserved aortic homografts seems to be a promising 
step in the treatment of aortobronchial, aortoesophageal, nd aortointestinal fistulae. 
This technique has a low operative mortality rate and may prevent reinfection. (J Vasc 
Surg 1997;26:11-7.) 
Fistulae that originate from mycotic aneurysms or 
prosthetic grafts of the thoracic or abdominal aorta 
may communicate with various organ systems. This 
pathologic communication between the aorta or a 
prosthetic aortic graft and the lung, the esophagus, 
or the bowel complicates a major vascular infection, 
which is the primary event, whereas the erosion into 
the adjacent structure is the secondary event. The 
lack of a consistently effective operative treatment 
results in mortality rates from 30% to 80%. 1-3 Subse- 
quent  reinfection of implanted prosthetic grafts-- 
either extraanatomic or in situ--leads to persistence 
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of the infection, which necessitates repeated reopera- 
tions and long-term antibiotic treatment. Cryopre- 
served homograft heart valves and homograft arteries 
are assumed to be infection-resistant 4,s and are sup- 
posed to reduce the rates of perioperative mortality 
and morbidity that are associated with mycotic aneu- 
rysms or prosthetic graft infection of the aorta. 6-8 
This study presents our early experience with in situ 
repair of  aortobronchial, aortoesophageal, nd aor- 
tointestinal fistula using ctTopreserved aortic ho- 
mografts. 
PAT IENTS AND METHODS 
Patients 
Between April 1994 and June 1996, 11 consecu- 
tive patients (Tables I and II) with a mean age of 
62 _+ 10 years (range, 45 to 76 years) underwent 
operation for aortobronchiat (five patients), aorto- 
esophageal (two patients), and aortointestinal (four 
patients) fistulae. There were five patients with fistu- 
lae that originated from a mycotic aortic aneurysm 
and six with fistulae involving a prosthetic aortic 
11 
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Table I. Patient characteristics: thoracic aorta 
Patient 
1 2 3 4 5 6 7 
Age (yr) 61 45 55 69 74 69 68 
Sex Male Male Male Male Male Male Female 
Diagnosis MA PGI PGI MA MA MA MA 
First operation 4/71 3/95 
Diagnosis of primary operation Coarctation Type B 
of the aorta dissection 
Preoperative CT/Angio CT CT/MR CT CT CT CT 
diagnostic tests 
Type of fistula AB AB AE AE AB AB AB 
Infectious agent SICN SKN None None ENC None SKN 
Date of operation 5/94 6/94 5/95 10/95 4/96 4/96 6/96 
Postoperative None None Homograft None Hematothorax None None 
complications stenosis 
Duration of 21 21 90 90 60 28 28 
hospitalization 
(days) 
Follow-up time (mo) 31 26 17 14 8 8 6 
Method of follow-up Anglo CT/TEE MR/TEE CT CT CT 
MA, Mycotic aneurysm; PGI, prosthetic graft infection; AB, aortobronchial fistula; AE, aortoesophageal fistula; SKN, coagulase-negative 
staphylococci; ENC, enterococci; CT, computed tomography; Anglo, angiography; TEE, transoesophageal chocardiography; MR, 
magnetic resonance angiography. 
Table I I .  Patient characteristics: abdominal aorta 
PaHent 
8 9 10 11 
Age (yr) 57 61 76 46 
Sex Male Male Male Male 
Diagnosis PGI PGI PGI PGI 
Date of first operation 3/89 12/89 3/92 5/89 
Diagnosis of primary operation AA AOD AOD AA 
Preoperative diagnostic tests CT CT/Angio CT CT/Angio 
Infectious agent Escherichia co l i  Candida parapsilosis Staphylococcus a reus None 
Date of operation 6/95 12/95 3/96 6/96 
Postoperative complications None Myocardial infarction None None 
Duration of hospitalization 28 7 28 28 
(days) 
Follow-up time (too) 18 - -  9 6 
Method of follow-up MR - -  CT CT 
PGI, prosthetic graft infection; AA, infrarenai aortic aneurysm; AOD, arterial occlusive disease; CT, computed tomography; Anglo, 
angiography; MR, magnetic resonance imaging. 
graft. Emergency surgery was performed in eight o f  
11 patients (73%). Preoperative sepsis with fever, 
leucocytosis, elevated C-reactive protein, and posi- 
tive blood cultures was found in six o f  l I patients 
(54%). The mean preoperative leucocyte count was 
12 + 4.2 × 10 a (range, 6 to 20 × 103), whereas the 
mean C-reactive protein level was 98 -+ 75 mg/L  
(range, 5 to 208 mg/L ) .  
Peripheral arterial occlusive disease was found in 
five patients (45%), coronary artery disease in six 
(54%), chronic obstructive pulmonary disease in six 
(54%), and chronic renal failure in five (45%). 
Thorac ic  aorta 
The thoracic aorta was affected in seven patients 
(Table I). Patient #2 had undcrgone aortoplasty with 
a Dacron patch for coarctation o f  the aorta 23 years 
earlicr. He had a large pseudoancurysm penetrating 
into the left lung. During surgery, a suture dehis- 
cence of  the Dacron patch was found. 
Patient #3 had graft replacement o f  the descend- 
ing thoracic aorta for chronic type B dissection. Two 
months later, he returned with a large pseudoaneu- 
rysm and an aortoesophageal fistula that originated 
from the proximal anastomosis distal to the origin o f  
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the left subclavian artery (Fig. 1). During surgery, a
dehiscence ofthe proximal anastomosis, a pseudoan- 
eurysm, and a mycotic aneurysm of the aortic arch 
and the distal third of the ascending aorta was found. 
The distal part of the ascending aorta, theaortic arch, 
and the proximal part of the descending thoracic 
aorta were replaced by two aorta descendens ho- 
mografts. Distally, the h0mograft was anasto- 
mosed directly to the prosthetic graft, and the 
anastomosis was sealed with gentamycin-impreg- 
nated fibrin glue. Eighteen months later, the pa- 
tient complained of weakness of the lower limbs. 
An angiogram demonstrated a stenosis of the distal 
part of the homograft, which was successfully 
treated with a self-expandable stainless teel stent 
(Wallstent, Schneider Europe, Btilach, Switzer- 
land; Fig. 2). 
Patient #4 had an aortoesophageal fistula from a 
large ruptured mycotic aneurysm of the descending 
aorta. He had circulatory arrest before surgery and 
arrived at the operating room under full cardiopul- 
monary resuscitation where cardiopulmonary bypass 
grafting through the groin vessels was instituted im- 
mediately. 
The four remaining patients had a ruptured my- 
cotic aneurysm of the proximal third of the descend- 
ing thoracic aorta with an aortobronchial fistula. 
Abdominal aorta 
Aortointestinal fistulae were found in three pa- 
tients (Table II). Patient #8 underwent an aortobi- 
iliac bifurcation grafting procedure for an infrarenal 
aortic aneurysm 6 years ago. An aneurysm of the 
proximal anastomosis developed, which ruptured 
into the retroperitoneal duodenum. 
Patient #9 had an inadvertent intestinal injury 
during the implantation ofan aortobiiliac bifurcation 
graft 3 years ago. He underwent two subsequent 
laparotomies for prosthetic graft infection and 
sought medical attention with a huge abscess in the 
right fossa iliaca nd an aortointestinal fistula involv- 
ing the right leg of the prosthesis. 
Patient #10 received an aortobiiliac bifurcation 
graft 2 years ago with subsequent resection of the 
sigmoid colon and the upper rectum for early post- 
operative intestinal ischemia. He sought medical at- 
tention for recurrent rectal bleeding as a result of a 
fistula from the proximal anastomosis to the rectal 
stump. 
Patient #11 received an aortobiiliac bifurcation 
graft 7 years ago for aortoiliac occlusive disease, with 
the proximal anastomosis 5 cm below the origin of 
the left renal artery. A large juxtarenal nd infrarenal 
Fig. 1. Computed tomographic scan shows a large pseu- 
doaneurysm from the proximal anastomosis 2 months after 
prosthetic graft replacement of the descending thoracic 
aorta for chronic type B dissection (patient #3) causing an 
aortoesophageal fistula. 
aortic aneurysm developed, which finally ruptured 
into the retroperitoneal duodenum. 
Preparation of the homograft 
Homograft selection and preparation has already 
been described elsewhere in detail, s,9 Briefly, the 
ascending aorta, he aortic arch, and the ntire dc- 
scending aorta is removed in a sterile fashion from 
heart-beating organ donors aged 18 to 40 years old 
who fulfill heart valve selection criteria for cryopre- 
served heart valve hom0grafts. 9 After harvesting, the 
great vessels arc immediately stored at 4 ° C in an 
ice-cold solution and sent to the European Ho- 
mograft Bank in Brussels, Belgium, where they are 
further prepared, measurcd, and thoroughly exam- 
ined by angioscopy for degenerative changes. Before 
and after decontamination by a low concentrated 
antibiotic ocktail, microbiologic tests arc performed 
of various tissue samples (Table III). The homografts 
are then transferred to an ice-cold cryoprotective 
solution, frozen in liquid nitrogen vapor to -100 ° C, 
and finally stored in the vapor phase of liquid nitro- 
gen at -180 ° C. The grafts are thawed and washed 
immediately before implantation. Only great vessels 
with a warm ischemia time less than 6 hours are 
removed. The time between the death of the donor 
and the beginning of the sterilization i  the Euro- 
pean Homograft Bank should be less than 18 hours. 
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Fig. 2. Aortogram 18 months after homograft replacement ofthe distal part of the ascending 
aorta, the aortic arch, and the proximal part of the descending aorta (patient #3). Right, 
Stenosis of the distal part of the homograft. Left, Successful relief of the homograft s enosis with 
a self-expandable stainless steel tent, reducing the peak pressure gradient over the homograft 
from 42 mm Hg to 13 mm Hg. 
Table I I I .  Microbiologic tests of 
homografts before and after decontamination 
Culture media 
Aerobic bacteria 
Anaerobic bacteria 
Fungi 
Mycobacterias 
Toxoplasma gondii 
Treponema p llidum 
Serology 
HIV-1 & HIV-2 antibodies (ELISA, IMF, WB) 
HIV-1-DNA 
HTLV- 1 
HBsAG 
anti-HBc, if positive, anti-HBs 
anti-HCV 
anti-HAV 
VDRL 
Q-fever-antibodies 
EBV-Monospot IgG+IgM 
CMV IgG + IgM 
Operative technique 
Descending aorta. The descending aorta is ap- 
proached by a left-sided posterolateral thoracotomy. 
Partial cardiopulmonary b pass with moderate hypo- 
thermia (30 ° C) is performed through the left groin 
vessels to support the distal part of the body, to 
reduce the declamping shock, and to limit the risks of 
postoperative neurologic complications) ° The de- 
scending thoracic aorta is clamped istal and proxi- 
mal to the aneurysm or the infected prosthetic graft 
from which the fistula originates. The aneurysm or 
the prosthetic graft is carefully freed from the adher- 
ent lung or the posterior mediastinum containing the 
esophagus. The aneurysm is opened longitudinally 
and resected, preserving important intercostal arter- 
ies. Otherwise, the prosthetic graft is totally resected. 
After minimal debridement, he homograft is in- 
serted end-to-end to the normal aorta using a single 
nonabsorbable running polypropylene suture. Lung 
lacerations are readapted only to prevent massive air 
leakage. 
In patients with mycotic aneurysms of the aortic 
arch and aortoesophageal fistulae involving file prox- 
imal anastomosis of the descending thoracic graft, 
deep hypothermic circulatory arrest was necessary to 
replace the proximal ascending aorta, the aortic arch, 
and the proximal descending aorta. The arch vessels 
were reimplanted into the homograft; distally, the 
homograft was anastomosed to the proximal part of 
the descending thoracic prosthetic graft. The anasto- 
mosis was secured with gentamycin-impregnated fi- 
brin glue. 1 
Abdominal aorta. The abdominal aorta is ap- 
JOURNAL OF VASCULAR SURGERY 
Volume 26, Number 1 Vogt et al. 15 
proached through a median laparotomy or by a left 
retroperitoneal incision as convenient. The normal 
aorta and iliac vessels distal and proximal to the 
prosthetic graft are prepared, the densely adherent 
intestinal package is carefully freed, the prosthetic 
graft is removed, and a homograft is inserted end-to- 
end as described above. Intestinal lesions are over- 
sewn only if macroscopically identified. One patient 
underwent excision of three different segments of the 
small intestine, which were subsequently anasto- 
mosed to spare the patient an ilcostomy. One patient 
underwent partial replacement of the proximal part 
of an aortobiiliac bifurcation graft, which contained 
the aortointestinal fistula. The tube homograft was 
anastomosed to the distal part of the bifurcated pros- 
thesis, and the anastomosis was secured with genta- 
mycin-impregnated fibrin glue. In the third patient 
with an secondary aortointestinal fistula, which 
drained through the upper rectal stump, the bifurca- 
tion prosthesis was removed and the upper rectal 
stump was shortened and closed. 
Microbiologic analysis and antibiotic treat- 
ment. During surgery, aspirates of pus, exudates, 
and tissue specimens were secured. Gram staining for 
aerobes and anaerobes were performed. After sur- 
gery, intravenous antibiotics were given according to 
the microbiologic results. The duration of antibiotic 
treatment was influenced by the intraoperative find- 
ings and the microbiologic results. 
Follow-up 
Follow-up information was obtained from the 
referring hospitals. Computed tomography, mag- 
netic resonance angiography, transesophageal cho- 
cardiography, intravenous digital subtraction angiog- 
raphy, or a combination of these were performed at 
discharge from the hospital, after 3 months, and after 
1 year. At the end of follow-up, patients and their 
family doctors were directly contacted. The average 
follow-up time was 14.3 _+ 8.2 months (range, 6 to 
31 months). 
RESULTS 
The operative mortality rate was 9%; one patient 
with an aortointestinal fistula originating from an 
infrarenal bifurcation prosthesis died from sudden 
cardiac death after 7 days. His postoperative course 
was uneventful; he was fully mobilized, had normal 
postoperative wound healing, full enteral nutrition, 
normal eukocyte count, a normal c-reactive protein 
value (<3 mg/ml),  and was ready for discharge to 
the referring hospital. He died despite immediate full 
cardiac life support. There were no hornograft- 
related, fistula-related, or infection-related early 
deaths. 
The mean hospital stay was 42 +_ 26 days (range, 
21 to 90 days), and the mean stay in the intensNe 
care station was 6.6 days (range, 1 to 42 days), where 
the patients were mechanically ventilated for a mean 
of 4.9 days (range, 1 to 28 days). There was one early 
reoperation--a rethoracotomy for persistent bleed- 
ing on the first postoperative day. Primary wound 
healing was normal in all patients. During surgery an 
infectious agent could be identified in seven of 10 
patients (Tables I and II). The mean duration of 
antibiotic treatment was 38 +_ 6 days (range, 28 to 
42 days). Except in one patient, hospital stays longer 
than 14 days were entirely a result of prolonged 
antibiotic treatment. After surgery, only one patient 
had postoperative s psis, which necessitated the use 
of catecholamines. The mean duration of postopera- 
tive fever was 2.8 -+ 0.9 days (range, 2 to 5 days). 
Neurologic omplications were not observed. 
There was one late reintervention--the patient 
who had combined replacement of the distal ascend- 
ing aorta, the aortic arch, and the proximal descend- 
ing aorta, with the homograft anastomosed directly 
to the descending thoracic prosthetic graft, had a 
progressive stenosis of the distal part of the ho- 
mograft. Eighteen months after surgery, the mean 
pressure gradient of 42 mm Hg was successfully 
reduced to 13 mm Hg by percutaneons placement of 
a self-expandable stainless teel stent (Fig. 2). 
To date, there were no late deaths or reinfections 
observed. Postoperative magnetic resonance angio- 
grams in five patients, conventional ngiograms (Fig. 
2) in two patients, computed tomographic scans in 
three patients, and transesophageal chocardiograms 
in five patients all appeared normal. After a mean 
follow-up of 14.3 + 8.2 months (range, 6 to 31 
months) neither homograft leakage, false aneurysms, 
perihomograft exudates, anastomotic aneurysms, 
nor, except in one, homograft stenosis could be ob- 
selwed. 
DISCUSSION 
The surgical treatment of aortoenteric fistulae 
that originate from either the diseased or recon- 
structed abdominal aorta has an invariably high mor- 
tality rate of 22% to 80%. >3~12 In addition, early 
amputation rates between 5% and 27% result in con- 
siderable long-term morbidity. 13~14 
The management of aortobronchial fistulae is 
mainly reported in case reports and consists of in situ 
graft replacement supported by pedicled omentum 
or muscle flaps. 15,16 A recent review of the surgical 
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repair for aortobronchial fistulae revealed a survival 
rate of only 76%) 7 The same might be true for 
aortoesophageal fistulae, where successful surgical 
treatment is individually reported. ~s,~9 
Whichever surgical technique is used--in situ re- 
placement, extraanatomic reconstruction, antibiotic- 
bonded grafts, muscle or omentum flaps, etc.--has 
little influence on the overall results. Each has its 
major drawbacks, for example, extraanatomic bypass 
grafts may subsequently become infected and have a 
lower patency rate. In situ repair is complicated by 
suture line infection and secondary graft infection. 
The successful root replacement technique with 
cryopreserved homograft heart valves in acute, de- 
structive aortic valve endocarditis 2° also implies the 
replacement of the proximal part of the ascending 
aorta--a pure valve and vascular in situ replacement 
in infected operative fields. This prompted us to use 
cryopreserved aortic homografts for the surgical 
treatment of various aortic fistulae. The use of ho- 
mografts allowed a safe and simple in situ repair and 
limited extensive periaortic debridement, resulted in 
a low operative mortality rate, reduced the length of 
hospital stay and the duration of postoperative anti- 
biotic treatment, and, to date, prevented early and 
late reinfection. The duration ofperioperativc antibi- 
otic treatment is empirically based on our &week 
antibiotic ourse in patients who undergo operation 
for aortic valve endocarditis using cryopreservcd ho- 
mograft heart valves and valved cardiac conduits. 
Actually, an intravenous antibiotic treatment for 3 to 
6 weeks is usually prescribed epending on the intra- 
operative findings, results of the bacteriologic exam- 
inations, the susceptibility esting, and the observed 
postoperative course. There was no reinfection ob- 
served in our patients during this follow-up. 
The reason why cryoprescrved homografts-- 
heart valves and arteries--seem to be clinically resis- 
tant to bacterial infections 6-8,2° is rather hypothetical, 
involving recipient immune cells, passive release of  
antibacterial substances by the graft, or physical and 
chemical homograft wall properties. 21
The use of flesh arterial allografts was abandoned 
years ago as a result of spontaneous rupture, throm- 
bosis, and late aneurysm formation. 22 In situ allo- 
graft replacement of infected infrarenal aortic pros- 
thetic grafts has been reported by IQeffer 23 and 
resulted in a mortality rate of 13.8%. After a mean 
follow-up of 19.6 -+ 14 months (range, 1 to 53 
months), 24% of their patients had had pathologic 
changes in their homograft and 9% required ho- 
mograft-related reoperation. 23The long-term fate of 
cryopreserved arterial homografts should be superior 
to fleshly implanted homografts, as cryopreservation 
preserves a digestion-resistant collagenous network 
similar to the glutaraldehyde-pretreatment of bio- 
prosthetic heart valves. 24 Concerning cryopreserved 
heart valves and valved cardiac conduits, the superi- 
ority of cryopreserved homografts over fresh allo- 
grafts is clearly supported by their excellent long- 
term results. 4 Even if the patients with cryopreserved 
vascular homografts require late homograft-rclated 
reoperation, the use of these conduits may serve as a 
temporizing maneuver that may help to eradicate the 
infection and may allow subsequent reconstruction 
with prosthetic material. Although the long-term 
behavior of cryopreserved aortic homografts i un- 
lmown, concerning major aortic infections with aor- 
tic fistulae, it is the high operative mortality rate that 
is still of major concern and that might be reduced 
with the use of these homografts. 6-s Therefore, we 
suggest that the surgical treatment of various fistulae 
that originate from the natural diseased or recon- 
structed thoracic or abdominal aorta to become a 
primary indication for the use of cryopreserved aortic 
homografts. 
We are aware that this study presents a small 
series of  patients with a very limited follow-up. Nev- 
ertheless, in these patients, homografts allowed a safe 
and simple in situ repair with a low early mortality 
rate and a satisfactory early and mid-term follow-up. 
Their hospital stay and postoperative antibiotic treat- 
ment was short and cost-effective. The use of cryo- 
preserved aortic homografts seems to be a promising 
step in the challenging treatment of aortoenteric, 
aortobronchial, and aortoesophageal fistulae, but the 
determination fits true value requires further obser- 
vation and longer follow-up periods. 
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